Neuroectodermal Tumors Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major neuroectodermal tumors markets are expected to exhibit a CAGR of 1.07% during 2024-2034.
The neuroectodermal tumors market has been comprehensively analyzed in IMARC's new report titled "Neuroectodermal Tumors Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Neuroectodermal tumors are a group of rare and diverse tumors that arise from the neural crest or primitive neural tissue. This condition can develop in several parts of the body, including the central and peripheral nervous systems. The symptoms and prognosis of these tumors vary depending on their location, size, and aggressiveness. Some common indications associated with the disease are persistent and severe headaches, nausea, vomiting, dizziness, balance and coordination problems, skin rashes, seizures, changes in vision, speech difficulties, weakness or numbness, cognitive impairment, back pain, fatigue, irritability, etc. The diagnosis of neuroectodermal tumors typically involves a combination of clinical evaluation, medical history assessment, and pathological examination. Several radiological imaging techniques, like magnetic resonance imaging (MRI) and computed tomography (CT) scans, are also used to visualize and locate cancerous cells. Additionally, molecular testing may be performed to detect specific genetic abnormalities or markers responsible for the underlying condition. The healthcare provider may further recommend a tissue biopsy, followed by a pathological examination, for the identification of the tumor type and grade in patients.
The increasing cases of genetic mutations or chromosomal irregularities that can modify the structure of DNA or its associated proteins, thereby affecting gene expression, are primarily driving the neuroectodermal tumors market. In addition to this, the rising incidence of viral infections, which either promote the uncontrolled proliferation of abnormal cells or interfere with the host's immune system, is also creating a positive outlook for the market. Moreover, the widespread adoption of high-dose chemotherapy with stem cell transplant to maximize the destruction of tumors as well as reduce the likelihood of recurrence is further bolstering the market growth. Apart from this, the inflating application of targeted therapies that specifically disrupt certain molecules or pathways involved in the formation of tumors while limiting the damage to healthy cells is acting as another significant growth-inducing factor. Additionally, the emerging popularity of retinoid therapy owing to its numerous benefits, such as slowing down disease progression, promoting apoptosis, and improving overall treatment outcomes in patients, is expected to drive the neuroectodermal tumors market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the neuroectodermal tumors market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for neuroectodermal tumors and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neuroectodermal tumors market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the neuroectodermal tumors market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the neuroectodermal tumors market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current neuroectodermal tumors marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the neuroectodermal tumors market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the neuroectodermal tumors market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the neuroectodermal tumors market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of neuroectodermal tumors across the seven major markets?
What is the number of prevalent cases (2018-2034) of neuroectodermal tumors by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of neuroectodermal tumors by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with neuroectodermal tumors across the seven major markets?
What is the size of the neuroectodermal tumors patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of neuroectodermal tumors?
What will be the growth rate of patients across the seven major markets?
Neuroectodermal Tumors: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for neuroectodermal tumors drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neuroectodermal tumors market?
What are the key regulatory events related to the neuroectodermal tumors market?
What is the structure of clinical trial landscape by status related to the neuroectodermal tumors market?
What is the structure of clinical trial landscape by phase related to the neuroectodermal tumors market?
What is the structure of clinical trial landscape by route of administration related to the neuroectodermal tumors market?
The neuroectodermal tumors market has been comprehensively analyzed in IMARC's new report titled "Neuroectodermal Tumors Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Neuroectodermal tumors are a group of rare and diverse tumors that arise from the neural crest or primitive neural tissue. This condition can develop in several parts of the body, including the central and peripheral nervous systems. The symptoms and prognosis of these tumors vary depending on their location, size, and aggressiveness. Some common indications associated with the disease are persistent and severe headaches, nausea, vomiting, dizziness, balance and coordination problems, skin rashes, seizures, changes in vision, speech difficulties, weakness or numbness, cognitive impairment, back pain, fatigue, irritability, etc. The diagnosis of neuroectodermal tumors typically involves a combination of clinical evaluation, medical history assessment, and pathological examination. Several radiological imaging techniques, like magnetic resonance imaging (MRI) and computed tomography (CT) scans, are also used to visualize and locate cancerous cells. Additionally, molecular testing may be performed to detect specific genetic abnormalities or markers responsible for the underlying condition. The healthcare provider may further recommend a tissue biopsy, followed by a pathological examination, for the identification of the tumor type and grade in patients.
The increasing cases of genetic mutations or chromosomal irregularities that can modify the structure of DNA or its associated proteins, thereby affecting gene expression, are primarily driving the neuroectodermal tumors market. In addition to this, the rising incidence of viral infections, which either promote the uncontrolled proliferation of abnormal cells or interfere with the host's immune system, is also creating a positive outlook for the market. Moreover, the widespread adoption of high-dose chemotherapy with stem cell transplant to maximize the destruction of tumors as well as reduce the likelihood of recurrence is further bolstering the market growth. Apart from this, the inflating application of targeted therapies that specifically disrupt certain molecules or pathways involved in the formation of tumors while limiting the damage to healthy cells is acting as another significant growth-inducing factor. Additionally, the emerging popularity of retinoid therapy owing to its numerous benefits, such as slowing down disease progression, promoting apoptosis, and improving overall treatment outcomes in patients, is expected to drive the neuroectodermal tumors market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the neuroectodermal tumors market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for neuroectodermal tumors and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neuroectodermal tumors market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the neuroectodermal tumors market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the neuroectodermal tumors market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current neuroectodermal tumors marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the neuroectodermal tumors market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the neuroectodermal tumors market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the neuroectodermal tumors market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of neuroectodermal tumors across the seven major markets?
What is the number of prevalent cases (2018-2034) of neuroectodermal tumors by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of neuroectodermal tumors by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with neuroectodermal tumors across the seven major markets?
What is the size of the neuroectodermal tumors patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of neuroectodermal tumors?
What will be the growth rate of patients across the seven major markets?
Neuroectodermal Tumors: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for neuroectodermal tumors drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neuroectodermal tumors market?
What are the key regulatory events related to the neuroectodermal tumors market?
What is the structure of clinical trial landscape by status related to the neuroectodermal tumors market?
What is the structure of clinical trial landscape by phase related to the neuroectodermal tumors market?
What is the structure of clinical trial landscape by route of administration related to the neuroectodermal tumors market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NEUROECTODERMAL TUMORS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 NEUROECTODERMAL TUMORS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NEUROECTODERMAL TUMORS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 NEUROECTODERMAL TUMORS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NEUROECTODERMAL TUMORS - UNMET NEEDS
10 NEUROECTODERMAL TUMORS - KEY ENDPOINTS OF TREATMENT
11 NEUROECTODERMAL TUMORS - MARKETED PRODUCTS
11.1 List of Neuroectodermal Tumors Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 NEUROECTODERMAL TUMORS - PIPELINE DRUGS
12.1 List of Neuroectodermal Tumors Pipeline Drugs Across the Top 7 Markets
12.1.1 Afatinib - Boehringer Ingelheim
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. NEUROECTODERMAL TUMORS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. NEUROECTODERMAL TUMORS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NEUROECTODERMAL TUMORS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Neuroectodermal Tumors - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Neuroectodermal Tumors - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Neuroectodermal Tumors - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Neuroectodermal Tumors - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Neuroectodermal Tumors - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Neuroectodermal Tumors - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Neuroectodermal Tumors - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Neuroectodermal Tumors - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Neuroectodermal Tumors - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Neuroectodermal Tumors - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Neuroectodermal Tumors - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Neuroectodermal Tumors - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Neuroectodermal Tumors - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Neuroectodermal Tumors - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Neuroectodermal Tumors - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Neuroectodermal Tumors - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Neuroectodermal Tumors - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Neuroectodermal Tumors - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Neuroectodermal Tumors - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Neuroectodermal Tumors - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Neuroectodermal Tumors - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Neuroectodermal Tumors - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Neuroectodermal Tumors - Access and Reimbursement Overview
16 NEUROECTODERMAL TUMORS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NEUROECTODERMAL TUMORS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NEUROECTODERMAL TUMORS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NEUROECTODERMAL TUMORS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 NEUROECTODERMAL TUMORS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NEUROECTODERMAL TUMORS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 NEUROECTODERMAL TUMORS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NEUROECTODERMAL TUMORS - UNMET NEEDS
10 NEUROECTODERMAL TUMORS - KEY ENDPOINTS OF TREATMENT
11 NEUROECTODERMAL TUMORS - MARKETED PRODUCTS
11.1 List of Neuroectodermal Tumors Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 NEUROECTODERMAL TUMORS - PIPELINE DRUGS
12.1 List of Neuroectodermal Tumors Pipeline Drugs Across the Top 7 Markets
12.1.1 Afatinib - Boehringer Ingelheim
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. NEUROECTODERMAL TUMORS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. NEUROECTODERMAL TUMORS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NEUROECTODERMAL TUMORS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Neuroectodermal Tumors - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Neuroectodermal Tumors - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Neuroectodermal Tumors - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Neuroectodermal Tumors - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Neuroectodermal Tumors - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Neuroectodermal Tumors - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Neuroectodermal Tumors - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Neuroectodermal Tumors - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Neuroectodermal Tumors - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Neuroectodermal Tumors - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Neuroectodermal Tumors - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Neuroectodermal Tumors - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Neuroectodermal Tumors - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Neuroectodermal Tumors - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Neuroectodermal Tumors - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Neuroectodermal Tumors - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Neuroectodermal Tumors - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Neuroectodermal Tumors - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Neuroectodermal Tumors - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Neuroectodermal Tumors - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Neuroectodermal Tumors - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Neuroectodermal Tumors - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Neuroectodermal Tumors - Access and Reimbursement Overview
16 NEUROECTODERMAL TUMORS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NEUROECTODERMAL TUMORS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NEUROECTODERMAL TUMORS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
